269 related articles for article (PubMed ID: 29705869)
21. Electroencephalographic power spectral density profile of the orexin receptor antagonist suvorexant in patients with primary insomnia and healthy subjects.
Ma J; Svetnik V; Snyder E; Lines C; Roth T; Herring WJ
Sleep; 2014 Oct; 37(10):1609-19. PubMed ID: 25197807
[TBL] [Abstract][Full Text] [Related]
22. Pharmacodynamic effects of suvorexant and zolpidem on EEG during sleep in healthy subjects.
Struyk A; Gargano C; Drexel M; Stoch SA; Svetnik V; Ma J; Mayleben D
Eur Neuropsychopharmacol; 2016 Oct; 26(10):1649-56. PubMed ID: 27554636
[TBL] [Abstract][Full Text] [Related]
23. Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2014 Dec; 68(12):1429-41. PubMed ID: 25231363
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics, Safety, and Tolerability of Multiple Doses of the Novel Oxytocin Receptor Antagonist Cligosiban in Development for Premature Ejaculation: Two Randomized Clinical Trials in Healthy Subjects.
Muirhead GJ; Osterloh IH; Whaley S; van den Berg F
J Sex Med; 2019 Feb; 16(2):213-222. PubMed ID: 30612858
[TBL] [Abstract][Full Text] [Related]
25. Effect of suvorexant on nighttime blood pressure in hypertensive patients with insomnia: The SUPER-1 study.
Kario K; Yamasaki K; Yagi K; Tsukamoto M; Yamazaki S; Okawara Y; Tomitani N; Kanegae H
J Clin Hypertens (Greenwich); 2019 Jul; 21(7):896-903. PubMed ID: 30874378
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics, Safety, and Tolerability of Single Oral Doses of a Novel Oxytocin Receptor Antagonist-Cligosiban-in Development for Premature Ejaculation: Three Randomized Clinical Trials in Healthy Subjects.
Osterloh IH; Muirhead GJ; Sultana S; Whaley S; van den Berg F; Atiee G
J Sex Med; 2018 Nov; 15(11):1547-1557. PubMed ID: 30341006
[TBL] [Abstract][Full Text] [Related]
27. Effects of Suvorexant, an Orexin Receptor Antagonist, on Respiration during Sleep In Patients with Obstructive Sleep Apnea.
Sun H; Palcza J; Card D; Gipson A; Rosenberg R; Kryger M; Lines C; Wagner JA; Troyer MD
J Clin Sleep Med; 2016 Jan; 12(1):9-17. PubMed ID: 26194728
[TBL] [Abstract][Full Text] [Related]
28. Suvorexant for the treatment of insomnia in patients with Alzheimer's disease.
Hamuro A; Honda M; Wakaura Y
Aust N Z J Psychiatry; 2018 Feb; 52(2):207-208. PubMed ID: 29237271
[No Abstract] [Full Text] [Related]
29. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial.
Michelson D; Snyder E; Paradis E; Chengan-Liu M; Snavely DB; Hutzelmann J; Walsh JK; Krystal AD; Benca RM; Cohn M; Lines C; Roth T; Herring WJ
Lancet Neurol; 2014 May; 13(5):461-71. PubMed ID: 24680372
[TBL] [Abstract][Full Text] [Related]
30. Effects of benzodiazepine and orexin receptor antagonist on cognitive function revealed by auditory event-related potentials.
Shiga T; Hoshino H; Ochiai H; Osakabe Y; Kanno K; Horikoshi S; Miura I; Yabe H
J Psychopharmacol; 2021 Dec; 35(12):1488-1495. PubMed ID: 34330170
[TBL] [Abstract][Full Text] [Related]
31. Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial.
Herring WJ; Ceesay P; Snyder E; Bliwise D; Budd K; Hutzelmann J; Stevens J; Lines C; Michelson D
Alzheimers Dement; 2020 Mar; 16(3):541-551. PubMed ID: 31944580
[TBL] [Abstract][Full Text] [Related]
32. Accelerated Development of the Dual Orexin Receptor Antagonist ACT-541468: Integration of a Microtracer in a First-in-Human Study.
Muehlan C; Heuberger J; Juif PE; Croft M; van Gerven J; Dingemanse J
Clin Pharmacol Ther; 2018 Nov; 104(5):1022-1029. PubMed ID: 29446069
[TBL] [Abstract][Full Text] [Related]
33. The role of suvorexant in the prevention of delirium during acute hospitalization: A systematic review.
Adams AD; Pepin MJ; Brown JN
J Crit Care; 2020 Oct; 59():1-5. PubMed ID: 32480359
[TBL] [Abstract][Full Text] [Related]
34. Suvorexant for insomnia in patients with psychiatric disorder: A 1-week, open-label study.
Kishi T; Sakuma K; Okuya M; Ninomiya K; Oya K; Kubo M; Matsui Y; Nomura I; Okuyama Y; Matsunaga S; Iwata N
Neuropsychopharmacol Rep; 2019 Sep; 39(3):252-255. PubMed ID: 31283862
[TBL] [Abstract][Full Text] [Related]
35. [Preclinical and clinical results of dual orexin receptor antagonist, suvorexant (BELSOMRA(®)), a novel therapeutic agent for insomnia].
Tanaka Y; Aoki I; Ishine T; Renger JJ; Winrow CJ; Hisada S
Nihon Yakurigaku Zasshi; 2016 Jul; 148(1):46-56. PubMed ID: 27430679
[No Abstract] [Full Text] [Related]
36. Safety profile and clinical course of patients with insomnia administered suvorexant by initial treatment status in a post-marketing survey.
Sano H; Asai Y; Miyazaki M; Iwakura M; Maeda Y; Hara M
Expert Opin Drug Saf; 2019 Nov; 18(11):1109-1118. PubMed ID: 31478753
[No Abstract] [Full Text] [Related]
37. Safety, tolerability and pharmacokinetics after single and multiple doses of preladenant (SCH420814) administered in healthy subjects.
Cutler DL; Tendolkar A; Grachev ID
J Clin Pharm Ther; 2012 Oct; 37(5):578-87. PubMed ID: 22676397
[TBL] [Abstract][Full Text] [Related]
38. Multiple-dose clinical pharmacology of the selective orexin-1 receptor antagonist ACT-539313.
Kaufmann P; Ort M; Golor G; Kornberger R; Dingemanse J
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jun; 108():110166. PubMed ID: 33159976
[TBL] [Abstract][Full Text] [Related]
39. Can the Orexin Antagonist Suvorexant Preserve the Ability to Awaken to Auditory Stimuli While Improving Sleep?
Drake CL; Kalmbach DA; Cheng P; Roth T; Tran KM; Cuamatzi-Castelan A; Atkinson R; Singh M; Tonnu CV; Fellman-Couture C
J Clin Sleep Med; 2019 Sep; 15(9):1285-1291. PubMed ID: 31538599
[TBL] [Abstract][Full Text] [Related]
40. Preventive Effect of Suvorexant for Postoperative Delirium after Coronary Artery Bypass Grafting.
Tamura K; Maruyama T; Sakurai S
Ann Thorac Cardiovasc Surg; 2019 Feb; 25(1):26-31. PubMed ID: 30089761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
